SANTA MONICA, CA–(Marketwire – November 22, 2010) – The first annual Grayson’s Gift Foundation Event, hosted on November 11, 2010, was a huge success, raising more than $150,000. The charity event took place in the ballroom at Hotel Casa del Mar in Santa Monica.

Grayson’s Gift Foundation is a non-profit committed to raising money for the brain cancer research department at the Children’s Hospital of Los Angeles. Money was raised through ticket sales, an extravagant silent auction, and generous donations made by attendees.

The Grayson’s Gift Foundation was founded in 2010 by Leslie and Cliff Katab, whose son Grayson died from a brain tumor just over two years ago. Cliff Ketab said, “We went through many surgeries and chemo and countless days in hospitals, as well as traveling to Europe for experimental treatments. Although we did everything humanly possible, we lost our beloved baby boy two years ago.

“Pediatric brain cancer is the second leading cause of children’s death only behind social causes (car accidents, etc). Being immersed in this world taught us many life lessons. One thing we know is that we must help find a cure for these children. We created Grayson’s Gift Foundation just for this reason. Our charity donates its contributions directly to support research and training for pediatric brain cancer.”

A festive evening, it was a fusion of determined oncologists, compassionate celebrities, friends and family. Thrown into the mix were individual demonstrations of state-of-the-art brain-computer controlled games using NeuroSky technology. The day before the event, NeuroSky donated several games to the pediatric cancer ward at Children’s Hospital Los Angeles. At the event, David Westendorf, Vice President of NeuroSky, talked about how Children’s Hospital LA saved his niece’s life, and then he gave away NeuroSky-powered Mindflex games from Mattel as table prizes.

Celebrity guests included: actor Jonathon Goldsmith, recognized as “The Most Interesting Man in the World” in recent Dos Equis commercials; Corey Feldmen of “The Goonies”; Taylor Armstrong of Bravo’s “Real Housewives of Beverly Hills”; Vienna Girardi who starred in ABC’s “The Bachelor”;” Jennifer Elise Cox, known for her appearance in The Brady Bunch Movie; actress Delphine Chaneac; and actor James Preston of “The Gates.”

Photos: http://www.ballantinesbiz.com/Green_Oct_2010/CHLA/CHLA_GraysonsGift_112210.html

Click here to see all recent news from this company

MENOMONEE FALLS, WI–(Marketwire – November 22, 2010) – Assisted Living Concepts, Inc. (NYSE: ALC) stated today that it is disappointed with recent actions taken by the New Jersey Department of Health and Human Services and disputes allegations in an order issued by the Department on Friday, November 19, 2010. ALC will pursue appropriate legal remedies for dismissal of the order and related penalties.

“While at certain of our New Jersey buildings we have removed the assisted living licenses and changed our operations over to independent living communities, we are still in the process of registering those buildings with the New Jersey Department of Community Affairs as either multiple dwellings or boarding homes,” stated Laurie Bebo, President and Chief Executive Officer. “This registration process can be lengthy. In the interim, we have demonstrated that seniors living in these retirement communities either receive no health care services or receive services from a variety of home health or personal companion service companies just like many senior living communities in New Jersey. We are not marketing these buildings as assisted living facilities and the staff employed by these communities provides no health care services. We believe the communities will become registered as multiple dwellings or boarding homes under New Jersey’s Department of Community Affairs.

“We are disappointed with the recent actions by the Department of Health and Human Services as they are fully aware of our ongoing participation in the administrative registration process with the Department of Community Affairs. We hope the bureaucratic process will move along more quickly and look forward to an open dialogue with the Department of Community Affairs to accomplish the registrations. We continue to meet the expectations of the tenants who reside with us and believe last Friday’s action by the Department of Health unnecessarily creates disruption for the peace of mind and well being of our tenants and their families.” 

About Us

Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences comprising 9,305 residents in 20 states. ALC’s senior living residences typically consist of 40 to 60 units and offer residents a supportive, home-like setting and assistance with the activities of daily living. ALC employs approximately 4,100 people.

Forward-looking Statements

Statements contained in this release other than statements of historical fact, including statements regarding anticipated financial performance, business strategy and management’s plans and objectives for future operations, including management’s expectations about improving occupancy and private pay mix, are forward-looking statements. Forward-looking statements generally include words such as “expect,” “project,” “point toward,” “intend,” “will,” “indicate,” “anticipate,” “believe,” “estimate,” “plan,” “strategy” or “objective.” Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. In addition to the risks and uncertainties referred to in the release, other risks and uncertainties are contained in ALC’s filings with United States Securities and Exchange Commission and include, but are not limited to, the following: changes in the health care industry in general and the senior housing industry in particular because of governmental and economic influences; changes in general economic conditions, including changes in housing markets, unemployment rates and the availability of credit at reasonable rates; changes in regulations governing the industry and ALC’s compliance with such regulations; changes in government funding levels for health care services; resident care litigation, including exposure for punitive damage claims and increased insurance costs, and other claims asserted against ALC; ALC’s ability to maintain and increase census levels; ALC’s ability to attract and retain qualified personnel; the availability and terms of capital to fund acquisitions and ALC’s capital expenditures; changes in competition; and demographic changes. Given these risks and uncertainties, readers are cautioned not to place undue reliance on ALC’s forward-looking statements. All forward-looking statements contained in this report are necessarily estimates reflecting the best judgment of the party making such statements based upon current information. ALC assumes no obligation to update any forward-looking statement.

MUNDELEIN, IL–(Marketwire – November 22, 2010) – Educational guides on wound dressing packages can lead to increased patient safety and greater accuracy when applying the product, according to a just-released study in the Journal of Wound Ostomy and Continence Nursing (Journal of WOCN).  Published in the November/December issue of the peer-reviewed Journal of WOCN, the study included 173 clinicians and found that the nurses who used wound care dressings that had educational instructions attached to the outer package were 88 percent more likely to apply the products correctly than nurses who used the dressings in a traditional package.

“The results clearly show that just-in-time education in the form of educational instructions on a dressing package improves nurses’ confidence and accuracy when applying the dressing,” said Dea Kent, MSN, RN, NP-C, CWOCN, the author of the study and the manager of the Wound Ostomy Clinic at Riverview Hospital in Noblesville, Indiana. “The implication for manufacturers of wound dressings is that they should make it hard for the nurse to do the wrong thing by providing clear, easy-to-understand instructions that are accessible on the outside of the package so the nurse can review the process before treating the patient.”

The study used a wound dressing packaging system from Medline Industries, Inc. based on a concept of “just-in-time” education. Instructions for appropriate dressing use are attached to each package. The study was undertaken to assess the effects of this educational resource. The wound dressing used in the study was not familiar to the participants in order to more accurately assess the effect of the educational packaging and self-reported confidence with application.

The participants were randomly divided into two groups: a control group receiving the traditional wound education and an “intervention” group using Medline’s just-in-time educational packaging. None of the 62 nurses in the control group (using the traditional packaging) were able to apply the dressing correctly as compared to 68 of the 77 (88%) in the intervention group.

Similarly, 88% of the nurses in the intervention group reported that the educational packaging gave them confidence that they can correctly apply the dressing. Moreover, 71% in this group said they would change their nursing practice in relation to application of wound dressings based on the education on the package.

“The study findings provide evidence that manufacturers of wound dressings should apply just-in-time education techniques by placing an educational guide on all wound dressing packages in order to enhance the accuracy and safety of application and, ultimately, its efficacy in wound healing,” said Kent in the study’s conclusion.

Kent attributed the application failures by the nurses in the control group to a lack of knowledge about dressing application, since no information was available on the dressing package itself.

The study included nurses from a variety of backgrounds possessing all levels of education ranging from licensed practical nurse to Master of Science in nursing. Both novice and seasoned nurses were included. The study was conducted at eight facilities in central Indiana, including community hospitals, critical access hospitals, long-term care acute units, long-term care facilities and home health agencies.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

SUNNYVALE, CA–(Marketwire – November 22, 2010) – Healthmed Services, Ltd. (PINKSHEETS: HEME) announced that it has entered into a software development agreement with Veritas Software Systems. Veritas will produce for Healthmed 10 exclusive healthcare software suite systems by December 2011. “Healthmed is committed to bridging the information technology gap that plagues doctor, patient, and practice related issues that keep professionals and patients from experiencing the highest level of care and efficiency,” stated CFO Dale Paisley. Healthmed will continue to be committed to expanding its inventory of products to meet every aspect of efficiency and care, in additional to maximizing internal corporate growth and profitability.

Please read more about the Company and its product developments on its website: www.healthmedltd.com.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission.

CINCINNATI, OH–(Marketwire – November 22, 2010) – In the midst of flu season, millions of Americans are rushing to get vaccinated before becoming one of the approximately 200,000 flu victims the Centers for Disease Control (CDC) estimates are hospitalized every year. They aren’t the only ones suffering: according to study findings presented in a 2006 CNN story, the flu and other infectious disease outbreaks cost the nation’s employers about $10 billion a year.

That’s why the University of Cincinnati’s Midwest Center for Emerging Infectious Diseases (MI-CEID) exists. The center serves as a touchstone for advanced medical breakthroughs to provide protection and preparedness for biological events throughout the country — including bioterrorism, biological threats, pandemic outbreaks and even seasonal flu viruses.

“The best way to head off potential public health disasters is to have a targeted means to prevent, quickly diagnose, contain and treat infections. This can only be possible through diligent and comprehensive interdisciplinary research,” said Malak Kotb, Ph.D., chair of the department of molecular genetics, biochemistry and microbiology at the University of Cincinnati College of Medicine, and senior career research scientist at the VA Medical Center.

The MI-CEID is a unique model for collaboration across diversified medical disciplines, including:

• UC Academic Health Center;
• Local hospitals including the Cincinnati Children’s Hospital Medical Center;
• Environmental Protection Agency (EPA);
• VA Medical Center;
• Regional health department;
• Public safety agencies;
• Community leaders;
• Professional associations.

“Solutions to disease treatment and prevention require innovation — and you can’t be innovative and be in silos. We achieve the best outcomes by utilizing teams of people who are skilled in their areas of knowledge,” said Kotb. “By doing this, we create something novel and effective. We need to be ahead of the curve, and at UC we have the capabilities and technology to be able to make these strides in healthcare.”

Kotb credits the cross-disciplinary nature of UC’s research facility as key to the center’s early and continued successes. Whereas similar research centers rely on collaborators that may be spread across the country, the MI-CEID brings researchers from each of the organizations above, plus the university’s College of Medicine, under one roof for optimal communication and exchange of ideas and expertise.

To combat potential health threats, the collaborative team uses a state-of-the-art approach to identify and study different types of infectious bacteria, viruses and toxins to improve their detection. The team is also conducting research to identify genetic markers that may predict disease severity in individual patients and inform the most beneficial treatment for each based on genotypes of their DNA. 

“Once we find which genes are engaged in the disease process, we can determine how they are connected through the biological networks that influence disease,” said Kotb. “This allows us to create a roadmap that can predict responses, increase protection, reduce the severity or prevent the illness or disease altogether. This helps save time, money and lives when outbreaks occur.”

Organizations have been quick to realize the potential of the MI-CEID: the National Institutes of Health (NIH), the Department of Defense and Homeland Security, the Defense Threat Reduction Agency (DTRA) and other government agencies have tapped the center for research projects with national implications. In addition, Kotb cites the importance of private support via UC’s billion-dollar Proudly Cincinnati fundraising campaign. The center also relies on corporations that contribute to the research center’s ability to remain operational year-round and expand on its research capabilities.

But while this support can fund specific research initiatives, Kotb says that funding for truly cutting-edge research can sometimes be scarce. Financial support and partnerships are always being sought to further support research and discovery, build a stronger infrastructure, and attract high caliber scientists to effectively fight existing and emerging pathogens. These activities create jobs and boost the economy.

“Private industry is an essential ingredient to successful disease-mitigation and prevention strategies. Without private support to spur on ground-breaking research, essential studies –including those that can predict infection severity in different patients and/or can help suggest the best treatment strategies, and/or predict adverse reactions to certain drugs or vaccines can certainly save lives and reduce medical costs,” Kotb said.

There will always be another pandemic disease or public health scare, but with the UC’s MI-CEID program unique vision and collaborative model the treatments will be more timely and effective. For more information on this innovative program, visit www.uc.edu.

About the University of Cincinnati
 Ranked by the National Science Foundation among the top 20 public, urban research universities in the United States, the University of Cincinnati is the region’s largest employer, with a diverse student population of more than 39,000. UC’s faculty has distinguished themselves worldwide for their creative teaching and research, including members of the National Academy of Science, Institute of Medicine and winners of Tony, Grammy and Pulitzer Prizes. The University’s 15 Colleges set the foundation for a university dedicated to undergraduate, graduate, and professional education, experience-based learning, and research. U.S. News has described UC as one of 15 “up and coming” universities and Forbes Magazine named UC one of the world’s most beautiful campuses.

About the University of Cincinnati Foundation
The University of Cincinnati Foundation is leading Proudly Cincinnati: Tower of Strength, Rock of Truth, the University’s most ambitious campaign in history, supporting the vision for UC to become the finest urban research university in the United States. Proudly Cincinnati’s goal is to raise $1 billion by 2013. To date, approximately $696 million has been raised for scholarships, innovative teaching and groundbreaking research. For more information about the Proudly Cincinnati campaign, visit www.uc.edu/foundation.

The University of Cincinnati Foundation
University Hall, Suite 100
51 Goodman Drive
Cincinnati, OH 45219
www.ProudlyCincinnati.org
www.Twitter.com/ProudlyCincy
www.Facebook.com/ProudlyCincinnati

id=”nav_links”>

CINCINNATI, OH–(Marketwire – November 22, 2010) – Healthcare information technology solutions and services provider Technology Medical Partners (TMP), today announced that it has been awarded a Qualifying Therapeutic Discovery grant from the Federal government. The $113,000 grant was awarded as part of the Patient Protection and Affordable Care Act of 2010, which was passed by Congress to provide an immediate $1 billion boost to U.S. biomedical research and the small businesses conducting the research. Only companies with less than 250 employees were eligible for the tax credits or grants. TMP’s Clinical Quality Manager (CQM) provides real-time quality of care information allowing real-time actions and improvements to patient outcomes for caregivers.

According to the National Institute of Health’s web site, the Qualifying Therapeutic Discovery tax credit or grants are tax benefits targeted to therapeutic discovery projects that show a reasonable potential to:

• Result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions
• Reduce the long-term growth of health care costs in the United States
• Significantly advance the goal of curing cancer within 30 years

“Our CQM solution was created to help improve quality of care, reduce costs of care and improve income for health care providers, including increasing pay-for-performance, value based purchasing and meaningful use incentives,” stated Dr. Sunil Rao, managing partner at TMP. “This federal grant will help enhance our product development efforts so that we can continue to grow the number of patient-centered medical homes, clinics, hospitals, physicians and nurses that can benefit by having access to our system, delivering the right data at the right time. With better, timelier data, healthcare providers can provide more accurate evidence-based medicine and CMS reporting, which will help improve quality measures, patient outcomes and enhance their eligibility for government funds through pay for performance. As we like to say, quality data improves outcomes.”

TMP’s CQM solution allows healthcare providers to abstract quality of care data from any system; provide real time reports and dashboards to anyone; and support quality analytics and process improvement anywhere; functions that are not adequately provided by most electronic health records (EHR) systems to this level of detail. TMP’s CQM solution is built on the Microsoft SharePoint portal platform and abstracts patient information from disparate departments and systems, including EHR systems. Data is automatically abstracted, captured, populated and formatted into the report forms required by the Centers for Medicaid and Medicare Services. A quality database is maintained to drive all system reports, dashboards, analytics and process alerts.

About Technology Medical Partners
TMP delivers value-added information technology solutions and services to the Healthcare Industry. We focus on the business performance and quality improvement of healthcare providers (Hospitals, Clinics and Physician Practices). We bring a comprehensive array of software solutions, platform products and implementation services together with experience and leadership in Healthcare Solutions delivery. Founded in 2004, Technology Medical Partners is an Independent Software Vendor (ISV) focused on Healthcare Quality Improvement. We build Composite Software Solutions based on several technologies such as SharePoint and other Microsoft products as a Microsoft Certified ISV. We are also a partner with InterSystems and can provide our solutions built on the Cache` or Ensemble platforms. For more information, please visit www.t-m-partners.net. 

Click here to see all recent news from this company

WEST HARTFORD, CT–(Marketwire – November 22, 2010) – BroadcastMed, Inc., an interactive broadcasting company, has been recognized by the 2010 eHealthcare Leadership® Awards for its ORLive.com broadcasting portal, as a top overall internet site. The ORLive.com site was acknowledged along with The Cleveland Clinic and Mt. Sinai Medical Center. “We are extremely grateful and appreciative to be named a leading internet site by our peers in the health community,” said Ross Joel, CEO and Co-founder. Winners were recognized during a special presentation at the Fourteenth Annual Healthcare Internet Conference held November 15-17, 2010 in Las Vegas. 

Nearly 1,300 entries were received from a wide range of healthcare organizations. Factors considered in selecting the best overall internet site included delivery of strong health content, interactivity, medical care support, as well as strength of Web design and ease of navigation. Another Gold Award was bestowed on the Virtual Brain Tumor Board (MethodistHealth.or-live.com/vbtb) which BroadcastMed has developed for the Methodist University Hospital Neuroscience Institute. The Award was presented in the category of Best Health/Healthcare Content. Additionally, BroadcastMed’s work for CMEducation Resources was also cited with 12 additional awards. “Our commitment to provide comprehensive online solutions to a global audience makes this honor a huge motivator in continuing to educate our audiences with relevant content,” added Peter Gailey, President and Co-founder.

The eHealthcare Leadership Awards program exclusively recognizes the very best Web sites of healthcare organizations, online health companies, pharmaceutical/medical equipment firms, suppliers, and business improvement initiatives. The awards highlight the Internet’s role in achieving an organization’s business objectives and recognize the hard work that has gone into creating outstanding health Web sites. A total of 123 individuals familiar with healthcare and the Internet evaluated entries. Web sites were rated based on a standard of Internet excellence and how they compare with others in their group classification. For a list of winners, see: www.strategichealthcare.com/awards/winners.php. 

About BroadcastMed, Inc.

Since 1994, BroadcastMed has been providing online video solutions to hospitals, device manufacturers, and other health-related organizations. Our audience has access to thousands of hours of surgical broadcasts through our ORLive.com portal along with medical programs in other clinical disciplines, many of which include continuing medical education (CME) credit. 

Click here to see all recent news from this company

TUSTIN, CA–(Marketwire – November 22, 2010) – November is American Diabetes Month and Integrium LLC, a Contract Research Organization (CRO) with a therapeutic focus on cardiovascular and metabolic diseases, is at the forefront of clinical research to improve diabetes treatment. Eileen McAuley, Chief Operating Officer of Integrium, explains that the company has conducted 18 clinical trials of interventions for diabetes at 557 study sites. In addition to trials targeting diabetes, Integrium has conducted more than 100 cardiovascular and renal disease trials, which have an impact on diabetes care since diabetes is a leading cause of kidney failure and more than two-thirds of people with diabetes die of heart disease or stroke.

Integrium’s dedicated team of clinical researchers specializing in diabetes has pioneered therapies to improve the quality of life for people living with diabetes. Integrium’s Director of Project Management and Field Operations, Liza Moore, heads up a team with special expertise in wound healing. She explains that diabetic foot ulcers are among the most serious complications of the disease and untreated, often result in infection and amputation. “Our experience encompasses not only drugs to help manage blood glucose, but also medical devices such as bioengineered tissue products to speed wound healing. We are interested in preventing complications and effective treatment for those that can not be prevented.”

Integrium founder Dr. David H. G. Smith observes that the diabetes epidemic is not limited to the U.S. “One of our recent diabetes trials followed subjects in India, which has the largest diabetes population in the world, as well as subjects in the United States.” With its global reach, Integrium has completed trials in North America, Central and South America, the European Union and Asia for 12 of the top 20 biopharmaceutical companies.

About Diabetes
The United States is in the throes of a diabetes epidemic. An estimated 24 million children and adults have diabetes. Another 57 million others have pre-diabetes, elevated blood glucose levels that increase their risk of developing diabetes, heart disease and stroke.

One in ten American adults has diabetes and the Centers for Disease Control and Prevention (CDC) say that number could triple in the coming decades. The disease is the seventh leading cause of death in the U.S. and it is likely to be underreported as a cause of death.

Diabetes is a leading cause of kidney failure, blindness, amputations and pregnancy complications. Tighter blood glucose control reduces the symptoms and life-threatening complications of diabetes.

About Integrium, LLC
Integrium is a full-service clinical research organization (CRO) designing, conducting, and analyzing clinical trials for pharmaceutical research in dermatology, cardiovascular and metabolic disorders. It is committed to focused, specialized and long-term personalized service to its partners. It has a strong reputation for delivering high-quality management of clinical development programs. Combining the Integrium Clinical Excellence (ICE) study start-up and management methodology and therapeutic expertise leads sponsors to more confident, better-informed drug and device development decisions. For more information please visit www.integrium.com.

LANHAM, MD–(Marketwire – November 22, 2010) – The Residence on Greenbelt (www.theresidenceongreenbelt.com) will be filled with the holiday spirit when it opens its doors for the 1^st Annual Open House and Holiday Shoppe scheduled for Wednesday, December 15, 2010 from 11:00 am – 7:00 pm. The event will feature a variety of quality vendors including handcrafted items, jewelry, food products and more. A bake sale with delicious treats made by the residents will add to the festivities and enjoyment of the event. Hot apple cider, coffee and cookies for all who attend.

Event:
Open House and Holiday Shoppe

Date:
Wednesday, December 15, 2010

Location:
The Residence on Greenbelt
9885 Greenbelt Road, Lanham, MD 20706

Time:
11:00 am – 7:00 pm

Cost:
Free and open to the public

Activities:
More than a dozen vendor booths, bake sale, free treats and property tours

More Info:
Visit www.theresidenceongreenbelt.com or call (301) 486-1590

In conjunction with the Holiday Shoppe, The Residence on Greenbelt is hosting an Open House with guided tours of the property to learn more about living in a modern assisted living community. See first-hand how the community offers charm, extensive care and superior care, while allowing residents to experience its modern set of amenities including a Skype lounge and stately movie theatre equipped for the hearing impaired. Conveniently located on Greenbelt Road, The Residence on Greenbelt has recently undergone a complete renovation that has created a vibrant and interesting senior living residence, where residents can experience unrivaled service in modern and fun surroundings.

Four different service programs exist at The Residence on Greenbelt, providing the right match for the needs of seniors. In addition to Independent and Assisted Living, the community offers a Special Needs living area that provides for residents with higher acuity and mobility needs in an environment with features focused on maximizing independence while offering comfort and service. The Residence on Greenbelt also provides a unique memory care program through the Pathways Memory Care Program, an exceptional option for seniors with memory impairments as it offers a stimulating and engaging environment for residents created by each resident’s individual life story and peace of mind for their families and friends.

For more information about the Open House and Holiday Shoppe please visit www.theresidenceongreenbelt.com or call (301) 486-1590 or follow us on Facebook. For information about move-in opportunities or to set-up a private tour, please contact Patty Bay, Director of Sales and Marketing, at (866) 712-1172. The Residence on Greenbelt is located at 9885 Greenbelt Road, Lanham, MD 20706.

About IntegraCare:

IntegraCare’s mission is to “improve the quality of life for its employees, residents, and their families.” The company’s goal is to create an environment where its primary customer, the employee, experiences respect, dignity, and personal development. By providing this environment for its employees, the second half of our mission, “improve the quality life for our residents and their families,” will be achieved.

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – Nov. 22, 2010) – DiaMedica (TSX VENTURE:DMA) today announces that in accordance with the terms of the warrant indenture for those warrants issued on June 30, 2010 the Company has provided the required written notice to holders of such warrants that the expiry date has been accelerated to the close of business December 22, 2010.

Under the terms of the indenture and the broker warrant certificates, if the 10-day volume weighted average trading price of the common shares of DiaMedica on the TSX Venture Exchange exceeds $0.75, then at any date subsequent to this date, the expiry date of the warrant shall be the day that is 30 days following the later of (i) the date that written notice of the accelerated expiry is sent to warrantholders; and (ii) the date on which the announcement of the warrant expiry acceleration is made by news release. As of the close of business on November 19, 2010, the 10-day volume-weighted average trading price of the common shares exceeded $0.75. Warrants may be exercised through payment of the exercise amount of $0.50 per full warrant up to the close of business on December 22, 2010. If all of the 6,215,000 outstanding warrants subject to this acceleration are exercised, DiaMedica will receive additional proceeds of $2.8 million. Any warrants not exercised prior to the accelerated expiry date and time will expire without any further action being taken.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for type I diabetes, type 2 diabetes and other disorders. DiaMedica has completed two successful proof-of-concept II studies with DM-71 and DM-99, which demonstrate human efficacy in lowering blood glucose levels in patients with type 2 diabetes.

DiaMedica’s lead product DM-199 is a novel next generation recombinant form of DM-99, which has shown the potential to increase insulin sensitivity, reduce the autoimmune attack and trigger proliferation of pancreatic beta cells, neural stem cells and bone marrow cells. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”. For further information please visit www.diamedica.com.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters.
Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

RESEARCH TRIANGLE PARK, NC–(Marketwire – November 22, 2010) – The population of Brazil, Russia, India and China, roughly three billion people, coupled with these countries’ growing emphasis on strong physician-patient relationships, makes Emerging Markets a hotbed of clinical research activity, according to a new study. 

Emerging Markets Clinical Development Series: Brazil, Russia, India and China (BRIC) provides in-depth analysis on each of these countries’ benefits, advantages and challenges. The study is the latest in a series of studies from Cutting Edge Information about managing clinical trials in Emerging Markets. According to the research, patient availability is one of the top reasons driving drug companies to look to Emerging Markets for clinical trial management.

“Overall, the benefits outweigh the challenges of entering these markets,” said Jason Richardson, president of Cutting Edge Information. “Patients’ respect for their physicians’ recommendations in these markets provides clinical teams with a better chance to finish clinical testing with complete data and on time.”

A scientific advantage of the new clinical model is that much of the patient population is treatment naive, meaning that they have not already used other treatments that could change clinical results. These treatment-naive patients provide clearer effectiveness results when testing new medications. 

Emerging Markets Clinical Development Series: BRIC (http://www.cuttingedgeinfo.com/bric-clinical-trials/) provides quantitative analysis of patient availability and retention within the BRIC countries.

“For example, clinical development executives ranked India as the emerging market with the greatest patient availability, followed closely by China,” said Shaylyn Pike, senior research analyst at Cutting Edge Information. “With regard to patient retention, China, with the largest population of any country, took the top spot, followed by India.”

The new research study analyzes the potential of the BRIC markets to fulfill clinical protocols and ultimately realize significant cost and time savings. It is designed to provide clinical development teams with best practices, strategies and metrics to develop the strongest possible Emerging Markets strategies:

• Eliminate stakeholder confusion about BRIC strategy
• Master trial management in Emerging Markets
• Clarify advantages and disadvantages to boost success rates

Click here to see all recent news from this company

BALTIMORE, MD–(Marketwire – November 22, 2010) – Prometric, the leading provider of testing and assessment services, today announced that it has signed an exclusive long term contract with the American College of Radiology to convert its paper and pencil Diagnostic Radiology In-Training exam (DXIT™) to computer based format for the first time in the exam’s history. Prometric will also manage the final paper based administration for the College, which will occur in February 2011.

Beginning in 2012, physicians in residency training programs served by the American College of Radiology will be able to take the Diagnostic Radiology In-Training exam on a computer at any of Prometric’s hundreds of secure test centers across North America. The computerized test will also be available at select non-U.S. locations. In addition to the increased exam accessibility, computerized delivery will enable candidates to use convenient online registration and their residency programs will receive their scores much more quickly than with the paper based version.

“As a leading test services provider our goal is to work with each client to design a test program that matches their unique needs and requirements,” said Bill Murtagh, senior vice president, sales and client services at Prometric. “The logistical details surrounding paper based exams, such as exam publishing, printing, shipping, scanning, scoring or security, are more manually laborious, and can add time to the overall test process. It also requires a longer turnaround to produce scores, which the residency programs are obviously anxious to get. Offering the test in a modern computerized format will create efficiencies throughout the entire test lifecycle, speeding up the entire process and making it more manageable for the College.”

“Historically, the paper and pencil version of the Diagnostic Radiology In-Training Exam has been offered to candidates once per year,” said Ronald Freedman, assistant executive director, education, marketing, and business development at the American College of Radiology. “Computerizing the test allows us to better leverage technology to enhance security, widen the window of time during which it is available, facilitate easy access for our residents and get the residency programs their scores more quickly.”

About Prometric

Prometric, a wholly-owned subsidiary of ETS, is the recognized global leader in technology-enabled testing and assessment services. Its comprehensive suite of services, including test development, test delivery and data management capabilities, allows clients to develop and launch global testing programs as well as accurately measure program results and data. Prometric reliably delivers and administers more than nine million tests a year on behalf of approximately 400 clients in the academic, professional, healthcare, government, corporate and information technology markets. It delivers tests flexibly via the Web or by utilizing a robust network of more than 10,000 test centers in 163 countries. For more information, please visit www.prometric.com.

About the American College of Radiology

The 34,000 members of the American College of Radiology include radiologists, radiation oncologists, medical physicists, interventional radiologists and nuclear medicine physicians. For over three quarters of a century, the ACR has devoted its resources to making imaging safe, effective and accessible to those who need it.

The mission of the ACR is to serve patients and society by maximizing the value of radiology, radiation oncology, interventional radiology, nuclear medicine and medical physics by advancing the science of radiology, improving the quality of patient care, positively influencing the socio-economics of the practice of radiology, providing continuing education for radiology and allied health professions and conducting research for the future of radiology.

Click here to see all recent news from this company

SUNNYVALE, CA–(Marketwire – November 22, 2010) – Healthmed Services, Ltd. (PINKSHEETS: HEME) is pleased to announce the launch of “HealthTrac” software. HealthTrac is a Web-based open-source practice management solution for hospitals and physicians focusing on creating practice management as well as sales and marketing. Healthmed is committed to the continued expansion of its state of the art products that meet the demands of the healthcare industry.

According to Compass Intelligence, the U.S. market for health information technology will expand to $85 billion in 2014 from an estimated $73.1 billion in 2010, representing a 4.5 percent compound annual growth rate. Analysts have reported that nearly $2.5 trillion in healthcare was spent in 2009, which was $134 billion more than the previous year, when healthcare consumed 16.2 percent of the gross domestic product.

Please read more about the Company and its product developments on its website: www.healthmedltd.com.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission.

LOUISVILLE, CO–(Marketwire – October 30, 2010) –  GlobeImmune Inc. today announced additional data from the GI-5005-02 Phase 2b study demonstrating that GI-5005, the Company’s investigational Tarmogen^® product, improved sustained virologic response (SVR) by 12% in patients with genotype 1 chronic hepatitis C virus (HCV) infection who had failed prior treatment with standard of care (SOC, pegylated-interferon alpha 2a plus ribavirin). This study suggests that GI-5005 may have the potential to be the first successful therapeutic vaccine for patients chronically infected with HCV. 

Paul J. Pockros, M.D., of Scripps Clinic will deliver the oral presentation of the results in a late-breaker session at 6 p.m. EDT Monday November 1, 2010 at the 61^st Annual Meeting of the American Association for the Study of the Liver Diseases (AASLD) in Boston.

On an intent-to-treat basis (subjects who received at least one dose of combination therapy), prior non-responders receiving GI-5005 plus SOC as a triple therapy had an SVR rate of 17%, compared to an SVR rate of only 5% in patients receiving SOC alone. Prior non-responders in this study were defined as patients who did not clear virus after a minimum of 12 weeks of SOC, including null responders, poor responders, and partial responders. Relapsers and on-treatment breakthroughs were not enrolled in the study. The most common adverse events associated with GI-5005 were injection site reactions that were generally mild and transient in nature. Discontinuation rates due to adverse events in the GI-5005 triple therapy arm were comparable to the discontinuation rates in the SOC alone arm.

“Only 4-7% of patients with genotype 1 HCV who were null, poor or partial responders to their first course of pegylated interferon-based therapy would be expected to achieve a sustained virologic response with a second course of treatment,” said Dr. Pockros. “In this study, GI-5005 conferred a three-fold improvement in SVR, an important treatment effect in this challenging patient population.” 

Additional immunology data from the study will be presented in a poster on Tuesday, November 2, 2010 by John M. Vierling, M.D., of Baylor College of Medicine. These data show that GI-5005 improved HCV-specific T cell responses 10-fold over SOC alone in patients with the IL28B T/T genotype (~20% of chronically infected patients), the subgroup most likely to fail treatment with SOC alone. Patients with the IL28B T/T genotype receiving SOC alone had an HCV-specific cellular immune response that was 17-fold lower than patients in the IL28B C/C or C/T subgroups. The improved HCV-specific T cell immunity in IL28B T/T patients receiving GI-5005 plus SOC correlates with previously reported data that demonstrated GI-5005 increased SVR rates by 60% in interferon-naïve T/T patients compared to T/T patients receiving SOC alone.

“These data suggest that the fundamental deficit in patients carrying the T allele of the IL28B gene is a deficit in adaptive cellular immunity, the mechanism that GI-5005 was designed to address,” said David Apelian, M.D., Ph.D., Chief Medical Officer at GlobeImmune. “We are confident that GI-5005 will become a cornerstone of HCV therapy, particularly for difficult to treat populations, such as IL28B T/T patients.”

A 40 patient expansion of this study in patients having the IL28B T/T genotype was initiated last week to further explore the potential treatment effect of GI-5005 in this patient population.

GI-5005 is a therapeutic vaccine candidate designed to generate HCV-specific T-cell responses and improve virologic responses in patients with chronic hepatitis C virus infection. 

About GlobeImmune

GlobeImmune Inc. is a private company developing therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases. Tarmogens generate activated killer T cells that are designed to locate and eliminate virally-infected cells and/or cancer cells. The Company’s lead product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C virus (HCV) infection. GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV. The Company’s lead oncology program, GI-4000, targets cancers caused by mutated versions of the Ras oncoprotein. GI-4000 is being investigated in clinical trials for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer. In May 2009, the Company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the company’s website at www.globeimmune.com.

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company’s clinical trial programs and the results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.

LOUISVILLE, CO–(Marketwire – October 30, 2010) –  GlobeImmune Inc. today announced additional data from the GI-5005-02 Phase 2b study demonstrating that GI-5005, the Company’s investigational Tarmogen^® product, improved sustained virologic response (SVR) by 12% in patients with genotype 1 chronic hepatitis C virus (HCV) infection who had failed prior treatment with standard of care (SOC, pegylated-interferon alpha 2a plus ribavirin). This study suggests that GI-5005 may have the potential to be the first successful therapeutic vaccine for patients chronically infected with HCV. 

Paul J. Pockros, M.D., of Scripps Clinic will deliver the oral presentation of the results in a late-breaker session at 6 p.m. EDT today at the 61^st Annual Meeting of the American Association for the Study of the Liver (AASLD) in Boston.

On an intent-to-treat basis (subjects who received at least one dose of combination therapy), prior non-responders receiving GI-5005 plus SOC as a triple therapy had an SVR rate of 17%, compared to an SVR rate of only 5% in patients receiving SOC alone. Prior non-responders in this study were defined as patients who did not clear virus after a minimum of 12 weeks of SOC, including null responders, poor responders, and partial responders. Relapsers and on-treatment breakthroughs were not enrolled in the study. The most common adverse events associated with GI-5005 were injection site reactions that were generally mild and transient in nature. Discontinuation rates due to adverse events in the GI-5005 triple therapy arm were comparable to the discontinuation rates in the SOC alone arm.

“Only 4-7% of patients with genotype 1 HCV who were null, poor or partial responders to their first course of pegylated interferon-based therapy would be expected to achieve a sustained virologic response with a second course of treatment,” said Dr. Pockros. “In this study, GI-5005 conferred a three-fold improvement in SVR, an important treatment effect in this challenging patient population.” 

Additional immunology data from the study will be presented in a poster on Tuesday, November 2, 2010 by John M. Vierling, M.D., of Baylor College of Medicine. These data show that GI-5005 improved HCV-specific T cell responses 10-fold over SOC alone in patients with the IL28B T/T genotype (~20% of chronically infected patients), the subgroup most likely to fail treatment with SOC alone. Patients with the IL28B T/T genotype receiving SOC alone had an HCV-specific cellular immune response that was 17-fold lower than patients in the IL28B C/C or C/T subgroups. The improved HCV-specific T cell immunity in IL28B T/T patients receiving GI-5005 plus SOC correlates with previously reported data that demonstrated GI-5005 increased SVR rates by 60% in interferon-naïve T/T patients compared to T/T patients receiving SOC alone.

“These data suggest that the fundamental deficit in patients carrying the T allele of the IL28B gene is a deficit in adaptive cellular immunity, the mechanism that GI-5005 was designed to address,” said David Apelian, M.D., Ph.D., Chief Medical Officer at GlobeImmune. “We are confident that GI-5005 will become a cornerstone of HCV therapy, particularly for difficult to treat populations, such as IL28B T/T patients.”

A 40 patient expansion of this study in patients having the IL28B T/T genotype was initiated last week to further explore the potential treatment effect of GI-5005 in this patient population.

GI-5005 is a therapeutic vaccine candidate designed to generate HCV-specific T-cell responses and improve virologic responses in patients with chronic hepatitis C virus infection. 

About GlobeImmune

GlobeImmune Inc. is a private company developing therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases. Tarmogens generate activated killer T cells that are designed to locate and eliminate virally-infected cells and/or cancer cells. The Company’s lead product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C virus (HCV) infection. GI-5005 is designed to complement both the current standard of care and emerging novel therapies for HCV. The Company’s lead oncology program, GI-4000, targets cancers caused by mutated versions of the Ras oncoprotein. GI-4000 is being investigated in clinical trials for the treatment of pancreas cancer as well as other cancers that contain mutated Ras, including non-small cell lung cancer and colorectal cancer. In May 2009, the Company announced a global partnership with Celgene focused on the discovery, development and commercialization of multiple product candidates for the treatment of cancer.

For additional information, please visit the company’s website at www.globeimmune.com.

This news release and the anticipated presentation contain forward-looking statements that involve risks and uncertainties, including statements relating to initiation and progress of the Company’s clinical trial programs and the results from the clinical trials. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the release and anticipated presentation.

LEEDS, UNITED KINGDOM–(Marketwire – Oct. 29, 2010) – MYA Cosmetic Surgery is now offering Advanced Laser Lipolysis as a less invasive way to shape your body compared to conventional liposuction. Advanced Laser Lipo is ideal to remove unwanted deposits of fat that won’t respond to diet and exercise, perfect for those of us looking for quicker recovery times and a less invasive method of fat removal.

MYA is always looking to push forward with new techniques and methods developing in cosmetic surgery and we are proud to announce that we now offer Advanced Laser Lipolysis (A.L.L.) alongside our other popular services. While there are various forms of Liposculpture, A.L.L. is the one chosen by MYA since it actually removes fat from the body giving you the body shape and contour you desire.

John Ryan, MYA Chairman says, “I think it’s amazing. I’ve seen the operation being done myself and I’ve seen the great results that can be achieved. The beauty of this procedure is that it uses local anaesthetic and the procedure is much less disruptive to the patient’s life.” He continues “Liposuction is the number one procedure in the United States and Laser Liposuction is going to be really big in the future”. With over 1.6 million liposuction procedures performed worldwide in 2009*, A.L.L. is destined to be the next big thing for the cosmetic surgery industry.

The Laser Lipo treatment involves making tiny incisions and using the laser technology to ‘melt’ the fat away. After the unwanted fat is removed, the laser is used to encourage contraction to ensure an even, natural looking result is achieved. This is another great advantage of the procedure. Results can usually be seen from day one and the most popular areas for treatment include the abdomen, flanks (love handles), thighs, bra area and arms.

Advanced Laser Lipolysis is proving popular with both men and women as the benefits are comparable to traditional liposuction with a lot less downtime for the patient. The A.L.L. process provides a smooth, uniform result thanks to the accuracy of the Laser Lipolysis machine and our highly skilled surgeons.

One of our recent patients Charlotte comments, “I am a personal trainer and work out five times a week but despite the amount of exercise I do I just couldn’t get rid of the fat around my thighs and hips. I had the procedure over two weeks ago and I can already see a huge difference in my shape. I just wish I had it done sooner!”

Liposuction was the most popular cosmetic surgery procedure in the UK during 2009* with Breast Enlargement following closely behind and with no signs of slowing, Laser Liposuction shows great promise to capture the market and help people shift those stubborn areas of fat in a less invasive way.

For information please call 08000 27 97 76 or visit us at www.mya.co.uk/cosmetic-surgery/laser-liposuction.php

*From The International Society of Aesthetic Plastic Surgery’s “Raw Data – Total Procedures for Top 25 Countries”

Notes to editors:

MYA Profile

MYA (Make Yourself Amazing) Cosmetic Surgery Ltd is a pioneering cosmetic surgery provider brought to you by John Ryan, the former owner of Transform Medical Group and current chairman of Doncaster Rovers. John has over 25 years experience and has returned to cosmetic surgery enlisting the experience of the very best cosmetic surgeons and medical professionals in the industry. MYA pride themselves on their commitment to high quality service and medical supplies and have a comprehensive after-care policy. MYA’s world class expertise, competitive finance and state of the art national consultation centres are designed to ensure that Making Yourself Amazing is a reassuringly unique experience.

IRVINE, CA–(Marketwire – October 29, 2010) –  Sun Healthcare Group, Inc. (NASDAQ: SUNH) today announced that L. Bryan Shaul, chief financial officer, and Brandi Riddle, treasurer, will be presenting at the Credit Suisse 2010 Healthcare Conference on Thursday, Nov. 11, at 1 p.m. Mountain. 

The conference is being held at the Arizona Biltmore Resort and Spa in Phoenix, Ariz., Nov. 10-12. 

A copy of the presentation material will be available on the company’s web site at www.sunh.com immediately prior to Sun’s scheduled presentation.

About Sun Healthcare Group, Inc.  

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing, rehabilitative and related specialty healthcare services principally to the senior population in the United States. Sun’s core business is providing, through its subsidiaries, inpatient services, primarily through 166 skilled nursing centers, 16 combined skilled nursing, assisted and independent living centers, 10 assisted living centers, two independent living centers and eight mental health centers. On a consolidated basis, Sun has annual revenues of $1.9 billion and approximately 30,000 employees in 46 states. At Oct. 1, 2010, SunBridge centers had 23,189 licensed beds located in 25 states, of which 22,407 were available for occupancy. Sun also provides rehabilitation therapy services to affiliated and non-affiliated centers through its SunDance subsidiary, medical staffing services through its CareerStaff Unlimited subsidiary and hospice services through its SolAmor subsidiary.

MIAMI BEACH, FL–(Marketwire – October 29, 2010) –  When it comes to breast cancer, removal of the cancerous tissue is only part of the healing process. Reconstructing the breast at the same time can be critical for the wellbeing — and even survival — of the patient.

In support of Breast Cancer Awareness Month, New You magazine’s current issue addresses the issue of breast reconstruction at the time of initial surgery. In fact, say experts interviewed by New You, having a cosmetic or plastic surgeon involved right from the start means a more successful outcome for recreating a normal appearance and returning a woman’s sense of self and self-confidence.

“The cosmetic surgeon should be consulted right away, prior to any other surgery, and it should be a joint effort between the plastic or cosmetic surgeon and the breast surgeon,” says Dr. Michael S. Kluska, a board-certified plastic and cosmetic surgeon who practices near Pittsburgh, PA.

According to New You, the national consumer magazine for cosmetic surgery, the reasons for this include making sure the procedure performed by the breast surgeon removing the cancer is done so that optimal reconstruction is possible. The results can make a huge difference for the patient.

“Patients who undergo a mastectomy with simultaneous reconstruction tend to have better results long term than those who have the mastectomy [and] wait a few years,” Dr. Kluska told the magazine.

Kluska’s comments are supported by new research released last week in Toronto at the joint annual scientific meetings of the American Society of Plastic Surgery and the Canadian Society of Aesthetic Plastic Surgery, which showed that reconstruction of the breast immediately after mastectomy is associated with significantly improved breast-cancer-specific survival. Analysis of figures from the U.S. National Cancer Institute showed a 26% reduction in breast-cancer specific mortality for patients with immediate reconstruction; reasons included reduced depression and an improved sense of wellbeing.

About New You Magazine

New You is the official magazine of the American Academy of Cosmetic Surgery (AACS), published by Miami Beach-based New You Publishing, LLC. The mission of New You is to inform readers about the latest cosmetic procedures, to educate them about safety, cost and personal experience, and to locate the best possible cosmetic surgeon. For more information visit: http://newyoumag.com.

About The American Academy of Cosmetic Surgery

The American Academy of Cosmetic Surgery is a professional medical society dedicated to patient safety and physician education in cosmetic surgery. The AACS represents cosmetic surgeons in the American Medical Association through its seat in the AMA House of Delegates. Members of AACS are dermatological, facial plastic, head and neck, oral and maxillofacial, general, plastic, gynecological or ocular plastic surgeons specializing in cosmetic surgery. Founded in 1985, the AACS has over 2,500 members.

Click here to see all recent news from this company

MORRISVILLE, NC–(Marketwire – October 29, 2010) –  Banner Health, one of the largest nonprofit healthcare systems in the United States, with more than 23 hospitals in seven states, uses Redwood Software‘s Report2Web to achieve secure, fast, and efficient delivery and management of clinical, financial, and IT reports throughout the organization. Report2Web gives executives, along with clinical, staffing, and billing managers the specific information they need to keep the hospital system working at optimum levels at all times.

Every day, healthcare organizations rely on up-to-date staffing, patient load, and payment reports to manage the dynamic balance necessary to maintain quality of care. For Banner, these reports were often extremely large and complex. Typically, the final reports were emailed around the organization in their entirety and stored multiple times on multiple networks, creating a bandwidth and storage nightmare. In addition, the reports could not be split apart, which made simply finding key information an inexact, labor-intensive manual process, delaying critical decision making. “Since we have implemented Report2Web, essential reporting processes that once took many people and days to complete, now take one person a few minutes to accomplish,” says Bill Beaver, IT Director, Enterprise Integration Services for Banner Health. “We save time and money every day because of Report2Web.”

Through strict security and control, Report2Web gives managers only the information required for their specific role or task. “Banner has more than 6,000 unique reports, and we store this information indefinitely,” says Beaver. “We currently have more than seven million reports in our system. That’s equivalent to 24,000 four-drawer filing cabinets. These filing cabinets would completely fill 1.3 football fields. We needed a powerful solution to make this information more readily available and useful to us. With Report2Web we have it.”

Report2Web’s flexibility and ease of customizing reports resulted in even greater time savings. Now Banner can automatically create custom report packages and apply business rules to extract totals from specific reports. This allows managers to focus on analyzing key figures rather than just finding them. “This saves us immeasurable time. If the totals are correct, managers often don’t need to see the detail,” says Beaver. “If the totals are incorrect, the manager can quickly get that detail and investigate.”

For Banner, Report2Web was not just an improvement, it is a core solution. It provides the organization with the system they needed to enforce security and make critical, time-sensitive business decisions that directly impact the hospital’s critical care and financial health — every single day. Report2Web offers the flexibility and power to handle high volumes of sensitive information quickly and efficiently. As Banner Health continues to grow, they can focus on providing world-class healthcare while their report management system grows right along with them.

About Redwood
Redwood Software is a global company providing enterprise report management, workload automation, job scheduling, and financial process automation solutions that enable organizations to maximize the value of their information management and technology investments. Serving thousands of customer installations worldwide, Redwood helps companies meet the challenges of today’s competitive environment by delivering solutions that make business operations faster, more effective, and more efficient. Redwood serves businesses worldwide through locations in Europe, North America, and Australia, and through its alliances, including its strategic partnership with SAP AG.

About Banner Health
Headquartered in Phoenix, Banner Health is one of the largest, nonprofit health care systems in the country. The system owns or manages 23 acute-care hospitals, long-term care centers, outpatient surgery centers and an array of other services including family clinics, home care and hospice services, and a nursing registry. Banner Health is in seven states: Alaska, Arizona, California, Colorado, Nebraska, Nevada and Wyoming. In 2010, Thomson Reuters named Banner Health one of the Top 10 Hospital Systems in the U.S.

The original press release can be viewed at: www.redwood.com/banner-health

Redwood, Cronacle and Cronacle Mobile are trademarks or registered trademarks of Redwood Software. All other products or company names mentioned are used for identification purposes only and may be trademarks of their respective owners.

Click here to see all recent news from this company

RED BANK, NEW JERSEY–(Marketwire – Oct. 29, 2010) – Ansell Healthcare announces the launch of the Ansell Protects Program, a major new initiative aimed at helping healthcare facilities understand the risks associated with chemical allergies and providing solutions for them.

It is estimated that hand dermatitis affects up to 33% of all nurses, costing the U.S. an estimated $1 billion per year. The Ansell Protects Program was developed to improve the health of employees and also significantly reduce long-term costs for healthcare facilities.

Chemical allergies – otherwise known as Type IV allergies or allergic contact dermatitis – can cause physical, emotional and occupational issues for those affected. The only treatment is allergen avoidance. The Ansell Protects Program provides the tools to help healthcare facilities understand the impact of chemical allergies, assess their risk level, estimate their potential savings and find the right medical gloves to ensure they promote a healthy workplace.

“The effects of chemical allergies are wide-ranging, and the costs are high,” explained Patty Taylor, RN, BA, Vice President of Marketing – Medical Division, of Ansell Healthcare. “The Ansell Protects Program will help facilities understand the threat of chemical allergies – and will identify solutions that will foster better health and significant long-term savings.”

Costs associated with chemical allergies include diagnosis, workers’ compensation, disability, increased sick leave, decreased job productivity, and medical care costs.

Supporting its Ansell Protects Program are products that help reduce risk for facilities. Ansell is the first manufacturer to offer both a surgical and exam glove that help protect against Type I and Type IV allergies, including Derma Prene^® Ultra neoprene surgical gloves; Derma Prene^® Ultra HydraSoft^® hand friendly neoprene surgical gloves; and Micro-Touch^® NitraFree^™ nitrile examination gloves.

For more information on the physiology and effects of allergic contact dermatitis – including a breakdown of costs – visit www.AnsellProtects.com

About Ansell

Ansell Limited (“Ansell”) is a global leader in protection solutions. With operations in the Americas, Europe and Asia, Ansell employs over 10,000 people in 33 countries. Ansell designs, develops, manufactures and markets a wide range of surgical, examination, industrial and household gloves, protective clothing and condoms. People in over 100 countries around the world put their trust in Ansell’s innovative, high-quality solutions that offer superior protection, combined with high levels of comfort and performance. Operational headquarters are located in Red Bank, NJ.

UNION, NJ–(Marketwire – October 29, 2010) –  Considering that more than 80 percent of Americans will suffer from back pain at some point in their life, it isn’t surprising that Spine Centers of America is opening its second endoscopic spine surgery center in the New Jersey area in early November.

Advanced Spine Surgery Center, at 855 Lehigh Ave, Union, NJ, is a state-of-the-art facility that has been developed under the leadership of Bryan J. Massoud, M.D., a board certified, Fellowship-trained orthopedic spine surgeon. Dr. Massoud founded the New Jersey Back Institute and Spine Centers of America, which currently operates one other spine surgery center in New Jersey. Specializing in minimally invasive endoscopic laser spine surgery, diagnostic, and pain management procedures, Advanced Spine Surgery Center is an ambulatory surgery center that relieves patient neck and back pain when other treatments have failed. 

Key advantages of new endoscopic laser spine surgery over traditional open spine surgery include:

• Less trauma to body
• Reduced post-operative pain
• Less scarring and smaller scars
• Shorter recovery time
• Improved post-surgical function and mobility
• Reduced blood loss
• Reduction/elimination of time under general anesthesia

Advanced Spine Surgery Center has three Class C operating suites featuring the latest equipment and endoscopic spine surgery technologies. The operating suites, pre-op and post-op areas, occupying 10,000 sq. ft., will be staffed with board certified orthopedic spine surgeons, anesthesiologists, pain management physicians and nursing staff to provide outpatient care. The facility includes numerous medical offices for affiliated medical professionals.

The Grand Opening event for healthcare professionals will take place on November 16 with private previews available in advance by appointment. Healthcare professionals interested in attending should call 1.877.722.6008.

Spine Centers of America offers the advantage of numerous advanced endoscopic spine surgery techniques developed by Dr. Massoud and his associates that will be performed at the Advanced Spine Surgery Center. These procedures include:

• Anterior cervical endoscopic foraminotomy for treating bone spurs and foraminal stenosis
• Epiduragram-guided endoscopic discectomy to further enhance safety of discectomy procedures;
• The “between” technique in transforaminal endoscopic lumbar procedures for disc herniations.

Endoscopic laser spine surgery techniques that are employed by Advanced Spine Surgery Center use “twilight” or local anesthesia, which allows patients to remain alert during surgery and usually walk out of surgery under their own power. Dr. Massoud has personally performed more than 1000 endoscopic spine surgeries with a high success rate, enabling patients with debilitating spinal pain to get “back to life” free of pain. 

Spine Centers of America surgeons at Advanced Spine Surgery Center will treat spine conditions including: bone spurs; bulging disc, disc degeneration; disc tear; facet joint disease; failed back and neck surgery; foraminal stenosis; herniated disc; pinched nerve; radiculitis; radiculopathy; sciatica; spinal stenosis and spondylolisthesis. SCA’s surgeons have extensive experience performing the endoscopic spine procedures to diagnose or treat these conditions.

Because Spine Centers of America offers highly successful endoscopic techniques not yet available elsewhere, the new center, located minutes from Newark Airport, is expected to draw patients from across the country. Spine Centers of America hosts monthly seminars to educate the public about spinal conditions and advanced options for spinal pain relief via minimally invasive spine surgery techniques. For more information call 201.870.3030 or visit www.SpineCentersOfAmerica.com.

About Spine Centers of America:

Spine Centers of America offers the newest techniques in endoscopic spine surgery always performed by board certified spine surgeons. Considered a pioneer in minimally invasive spine surgery, SCA’s founder Dr. Bryan J. Massoud is among the most experienced Board certified orthopedic spine surgeons performing endoscopic laser spine procedures in the country. Recognized as an expert by his peers, Dr. Massoud instructs orthopedic residents and colleagues in new procedures such as kyphoplasty and endoscopic techniques. 

Click here to see all recent news from this company

ARLINGTON, VA–(Marketwire – October 28, 2010) –  Vangent, Inc., a leading global provider of information management and strategic business process solutions, today announced it was awarded the Patient Movement Item Tracking System (PMITS) Sustainment contract from the Military Health System in support of the Defense Health Services Systems Program Office.

PMITS is an award-winning MHS system, receiving the Agency Information Technology Award from Government Computer News in 2009. PMITS automatically tracks the storage of patient movement items during peacetime and its movement during contingency and wartime operations. PMITS ensures critical patient-movement equipment is available throughout patient evacuation to save critically injured warfighters’ lives.

Military commanders use PMITS to manage and redistribute patient movement assets to avoid shortages during patient evacuations. PMITS prevents the loss, shortages, and overages of aeromedical equipment by managing the equipment inventory, tracking its movement, and providing valuable information to personnel supporting aeromedical equipment, such as item identification, item location, and status. 

“Vangent is proud to support the Military Health System with a mission-critical system that provides essential equipment for our military’s wounded warriors,” said Kerry Weems, Senior Vice President and General Manager of Vangent’s Health Solutions business. 

Vangent’s subcontractor partner on this contract is Akimeka, LLC.

About Vangent, Inc. 
Vangent, Inc. is a global provider of consulting, systems integration, human capital management, and business process services to the U.S. federal and international governments, higher education institutions, and corporations. Vangent’s 8,500 employees support clients including the Centers for Medicare & Medicaid Services, the U.S. Departments of Defense, Education, Health and Human Services, Labor and Veterans Affairs; and the U.S. Office of Personnel Management, the U.S. Census Bureau, as well as Fortune 500 companies. Headquartered in Arlington, Virginia, the company has offices throughout the U.S. and in the U.K and Canada. For more information, visit www.vangent.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are those that do not relate solely to historical fact. They include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance, achievements or events. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “projects,” “likely,” “will,” “would,” “could” and similar expressions or phrases identify forward-looking statements. All forward-looking statements involve risks and uncertainties. The occurrence of the events described, and the achievement of the expected results, depend on many events, some or all of which are not predictable or within our control. In light of these risks and uncertainties, expected results or other anticipated events or circumstances discussed in this press release might not occur. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

MANHATTAN BEACH, CA–(Marketwire – October 28, 2010) – Beach Business Bank (OTCBB: BBBC) (the
“Bank”) is pleased to report its results of operations for the third
quarter of 2010, the year to date 2010, and the trailing 12 months which
includes the fourth quarter of 2009.

Third Quarter Highlights

-- Improving After-Tax Earnings.  For the trailing 12 months, the Bank
   earned $1,201,000, a historical earnings record for the Bank.
   All three of the Bank's offices: Orange County, Long Beach and
   Manhattan Beach, performed well in the quarter.


                                        Third
(U.S.         Third       Second       Quarter      First 9      First 9
 Dollars)  Quarter 2010 Quarter 2010     2009     Months 2010  Months 2009
           ------------ ------------ -----------  ------------ -----------
Net Income      450,000      256,000  (5,895,000)    1,058,000  (5,693,000)
           ------------ ------------ -----------  ------------ -----------

-- Loan Growth and Improving Funding Quality.  The Bank's niche lending
   businesses to physicians and dental professionals and the Bank's SBA
   lending practice showed strength, resulting in further loan
   originations. Development of non-interest-bearing deposits was strong
   during the quarter. The Bank's non-CD based deposits were 89% of total
   deposits at the end of the third quarter.


                                        9/30/2010   9/30/2010   9/30/2010
                                            vs.         vs.         vs.
% growth                                6/30/2010   12/31/2009  9/30/2009
                                        ---------   ----------  ----------
Net Loans                                    (.04)%      13.51%      30.22%
                                        ---------   ----------  ----------
Total Assets                                 18.7%        18.5%       18.7%
                                        ---------   ----------  ----------
Demand deposits (non-interest-bearing)       11.9%        52.0%       56.5%
                                        ---------   ----------  ----------
Total Deposits                               10.8%       22.71%       23.1%
                                        ---------   ----------  ----------

-- Total new loan commitments in the quarter amounted to more than
   $20 million. Non-interest bearing demand deposits totaled $49.1 million
   at quarter end. Overall deposits totaled $260.3 million at quarter end.
   Total assets increased by $47.6 million, to $302.5 million at
   quarter-end, as compared to $254.9 million for the same quarter end
   last year.

Stronger Operating Performance

                                                                    YTD
                          3Q 2010   2Q 2010   3Q 2009   YTD 2010    2009
                          --------  --------  -------   --------  -------

Return on Average Assets      0.60%     0.38%   (9.08)%     1.52%   (2.30)%
                          --------  --------  -------   --------  -------
Return on Average Common
 Equity                       6.09%     3.50%  (68.21)%    14.41%  (65.81)%
                          --------  --------  -------   --------  -------
Net Interest Margin           3.85%     3.98%    3.33%      3.92%    3.56 %
                          --------  --------  -------   --------  -------
Efficiency Ratio             65.79%    68.52%  144.56%     72.85%  110.35 %
                          --------  --------  -------   --------  -------
Tangible Book Value per
 Common Share             $   7.30  $   7.21  $  7.10   $   7.30  $  7.10
                          --------  --------  -------   --------  -------

“We are pleased to be able to report these strong results,” commented Jim
Gray, the co-chairman of the Bank’s board of directors. He continued, “We
are committed to helping the small businesses in our market area to get
back to hiring new employees and increasing their business again. The
recently passed Small Business Bill that the President signed into law on
September 27 will be a huge benefit for business banks like ours, and for
our small business customers.”

Robert Franko, president and chief executive officer of the Bank,
commented, “Our team of skilled bankers has worked tirelessly to achieve
these results, by continuing to build our franchises among small businesses
in our local market areas and among medical professionals nationwide. To
support further growth we continue to make additional provisions from our
core earnings to give us the necessary balance sheet strength. Our local
community has continued to provide us with strong core deposit
relationships, even as our funding costs have continued to decline. We are
fortunate to be located in the finest market areas in the world, and to
have the support of so many excellent and enduring business relationships.”

Loan Portfolio and Credit Quality

-- The Bank's Allowance for Loan & Lease Losses (ALLL) stood at
   $6.2 million or 2.5% of loans outstanding at the quarter end.
-- As of the quarter end, non-accrual loans stood at $5.0 million, with
   no other loans more than 30 days past due.
-- The Bank had net charge-offs of $361,000 in the quarter. The Bank
   provided $520,000 to the ALLL in the quarter.
-- As of the quarter end, the aggregate of non-accrual loans and OREO
   measured as a percentage of Capital and Reserves (sometimes referred to
   as the Texas Ratio) stood at 12.03%.
-- At the quarter end, the Bank's Total Risk-based Capital Ratio was
   14.89%, compared to the regulatory minimum of 10.0% to be
   "Well Capitalized."
-- The Bank's other regulatory Capital measurements also continued to be
   significantly above the regulatory minimums for Well Capitalized.
   For example, the Bank's Tier 1 Risk-Based Capital was 13.62%, compared
   to the regulatory minimum of 6.0%, and the Bank's Tier 1 Leverage Ratio
   was 11.88%, compared to the regulatory minimum of 5.0%.

Financial statements in the form of the Bank’s Call Report, as filed with
the FDIC, will be available on the Bank’s web site at
www.beachbusinessbank.com, and should be available for review or
downloading from the FDIC web site at www.fdic.gov shortly after the end of
this month.

Beach Business Bank is headquartered at 1230 Rosecrans Avenue, Lobby Level,
in Manhattan Beach, and has two other full-service offices at 180 E. Ocean
Blvd. in Long Beach, CA and at 650 Town Center Drive in Costa Mesa, CA. The
Bank is first and foremost a community business bank serving Los Angeles,
Long Beach, the South Bay and Orange County residents and businesses. The
Bank also has a division named The Doctors Bank®, which serves physicians
and dentists nationwide. In addition, Beach Business Bank provides loans to
small businesses, focused around the SBA 7(a) and Express lending programs.
For more information on the Bank, please visit www.beachbusinessbank.com or
call toll-free to (866) 862-3878.

“Safe Harbor” statement under the Private Securities Litigation Reform Act
of 1995:

The financial information in this press release is based on our unaudited
financial results. Certain statements in this press release, including
statements regarding the anticipated development and expansion of the
Bank’s business, and the intent, belief, and current expectations of the
Bank, its directors, or its officers, are “forward-looking” statements (as
such term is defined in the Private Securities Litigation Reform Act of
1995). Such forward-looking statements are subject to risks and
uncertainties and therefore the Bank’s actual results may differ materially
from those expressed or implied by such forward-looking statements. The
risks and uncertainties that the Bank is subject to include, but are not
limited to, risks related to the local and national economy, including
fluctuations in interest rates and costs and changes in economic policy;
the ability of the Bank to perform in accordance with its plans;
competition; regulatory matters; and other risks detailed in its filings
with the State of California Department of Financial Institutions and the
Federal Deposit Insurance Corporation. The Bank cautions readers not to
place undue reliance on any forward-looking statements. The Bank does not
undertake, and specifically disclaims any obligation, to revise any
forward-looking statements to reflect the occurrence of anticipated or
unanticipated events or circumstances after the date of such statements.

Summary Financial Information

The following tables present relevant financial data from
Beach Business Bank's recent performance.

                                           September  December   September
                                           30, 2010   31, 2009   30, 2009
                                           ---------  ---------  ---------
Balance Sheet Results (In thousands),
 except per share data:
       Total Assets                        $ 302,465  $ 255,321  $ 254,883
       Gross Loans                         $ 245,496  $ 217,361  $ 193,687
       Loans Held for Sale                 $   1,542  $   1,026  $   4,285
       Allowance for Loan Losses           $   6,188  $   6,870  $   6,819
       Total Net Loans                     $ 237,765  $ 209,465  $ 182,582
       Total Deposits                      $ 260,293  $ 212,083  $ 211,465
       Other Real Estate Owned             $       -  $   2,100  $   2,399
       Preferred Stock                     $   6,078  $   6,033  $   6,018
       Common Stock                        $  29,618  $  28,899  $  28,680
       Total Shareholders' Equity          $  35,696  $  34,932  $  34,698
       Net Loans to Deposits                   91.35%     98.77%     86.34%
       ALLL to Loans HTM                        2.54%      3.18%      3.60%
       Equity to Assets                        11.80%     13.68%     13.61%
       Ending Shares outstanding           4,055,972  4,036,984  4,036,984
       Ending Book Value per Common Share  $    7.30  $    7.16  $    7.10

                                                  Three Months Ended
                                           September  December   September
                                           30, 2010   31, 2009   30, 2009
                                           ---------  ---------  ---------
Quarterly Operating Results (In
 thousands):
       Net Interest Income                 $   2,780  $   2,230  $   2,041
       Non-interest Income                 $      57  $     583  $     302
       Non-interest Expense**              $   1,866  $   1,770  $   3,387
       Income Before Provision & Taxes     $     970  $   1,043  $  (1,045)
       Provision for Loan Losses           $     520  $     900  $   4,850
       Income Tax Expense                  $       -  $       -  $       -
       Net Income                          $     450  $     143  $  (5,895)
       Quarterly Return on Average Assets*      0.60%      0.22%     -9.08%
       Quarterly Return on Average Equity*      5.05%      1.63%    -58.11%
       Quarterly Net Interest Margin*           3.85%      3.46%      3.33%
       Quarterly Efficiency Ratio*             65.79%     62.93%    144.56%

                                            Nine Months Ended
                                           September  September
                                            30, 2010   30, 2009
                                           ---------  ---------
YTD Operating Results (In thousands):
       Net Interest Income                 $   7,909  $   6,410
       Non-interest Income                 $   1,072  $   1,060
       Non-interest Expense                $   6,542  $   8,243
       Income Before Provision & Taxes     $   2,438  $    (773)
       Provision for Loan Losses           $   1,380  $   4,920
       Income Tax Expense                  $       -  $       -
       Net Income                          $   1,058  $  (5,693)
       YTD Return on Average Assets*            0.38%     -2.30%
       YTD Return on Average Equity*            2.99%    -14.24%
       YTD Net Interest Margin*                 3.92%      3.56%
       YTD Efficiency Ratio*                   72.85%    110.35%


       *Percentages are reported on an annualized basis.
       Source: FDIC quarterly Call Reports for Beach Business Bank for the
       periods indicated.

MUNDELEIN, IL–(Marketwire – October 28, 2010) –  ClearCount Medical Solutions and Medline Industries, Inc. today announced that Hunt Regional Medical Center has become the first Texas hospital to deploy the most comprehensive technology for the prevention retained surgical sponge incidents. Hunt Regional Medical Center (HRMC) has implemented the SmartWand-DTX, part of ClearCount’s radio-frequency identification (RFID)-based platform that uniquely identifies each sponge so that they can be easily counted and detected. Medline is the exclusive distributor for the SmartWand-DTX and the SmartSponge System, the first FDA-cleared systems using RFID.

“The deployment of the latest safety technology in our OR is consistent with our commitment to both our community and our employees,” said Richard Carter, chief executive officer at HRMC. “We are pleased to be on the cutting edge of technology in this area, and our deployment reinforces our commitment to bringing the best care to the community we serve.”

“The SmartWand-DTX provides a safety net for human error. Anything that we can do to improve patient safety is extremely crucial. This technology not only allows our staff to operate at an exceptional level of patient safety, but also provides staff with a safer and more efficient method for reconciling our surgical counts,” said Katherine Magee, RN, OR director at Hunt Regional Medical Center.

HRMC has implemented the SmartWand-DTX into its full suite of operating rooms. The hospital is part of Hunt Regional Healthcare which is affiliated with Baylor Health Care System.

“We’re pleased to add Hunt Regional Medical Center to our rapidly expanding customer base,” said David Palmer, chief executive officer of ClearCount. “Their selection of our safety technology demonstrates the trend that many hospitals are now taking action to make retained sponge incidents a true ‘Never Event’ through the use of RFID technology.”

Despite designation as a “never event,” retained items are estimated to occur in one of every 1,000 to 1,500 abdominal surgical procedures, which can lead to hospital inefficiencies, unnecessary costs, serious infections and even death. Hospital infections add an estimated $30.5 billion to the nation’s hospital costs each year. In one study using a retrospective review of medical malpractice claims data from a statewide insurer in Massachusetts, sponge counts had been falsely thought to be correct in 76 percent of non-vaginal surgical cases involving retained sponges. “Falsely correct” sponge counts were attributed to team fatigue, difficult or long operations, sponges “sticking together,” shift changes or procedures with a large number of sponges. In July 2010, new Association of periOperative Registered Nurses (AORN) Recommended Practices for the Prevention of Retained Surgical Items highlighted that membership may consider use of adjunct technologies to enhance surgical count procedures in order to avoid retained incidents.

About ClearCount Medical Solutions
ClearCount Medical Solutions is a medical device company focused on patient safety solutions. ClearCount has assembled an extendable RFID-based platform that provides a comprehensive solution to improve efficiency while preventing medical errors, distributed exclusively by Medline. ClearCount Medical Solutions has been recognized with a Popular Science 2009 Best of What’s New Award, and has received additional recognition from TIME and WIRED magazines, the 2009 Wall Street Journal Technology Innovation Award, the International Design Excellence Award (IDEA) and more. ClearCount’s SmartSponge and SmartWand-DTX systems are the first RFID enabled systems for counting and detecting surgical sponges, thereby improving patient and OR safety, enhancing productivity, and reducing cost. To learn more, visit www.clearcount.com.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

OAKBROOK TERRACE, IL–(Marketwire – October 28, 2010) –  The Joint Commission Center for Transforming Healthcare today announced the establishment of a Leadership Advisory Council to guide the progress of the Center as it addresses and develops solutions to improve health care quality and patient safety. The first meeting of the Center’s Leadership Advisory Council will be held October 29.

Meeting three times a year, members of the Leadership Advisory Council include executives from among the Center’s major sponsors and CEOs representing the participating hospitals. The CEOs will serve on a rotating basis to allow new membership each year. The Council will be chaired by Mark Chassin, M.D., M.P.P., M.P.H., president, The Joint Commission. Council members are:

• Jack E. Bailey, GlaxoSmithKline
• Paul Chaffin, Ecolab
• George Halvorson, Kaiser Permanente
• Donny C. Lambeth, Wake Forest University Baptist Medical Center
• Alberto Mas, BD
• Rich Miller, Virtua
• Andy Mills, Medline Industries
• Ronald R. Peterson, The Johns Hopkins Hospital and Health System
• Thomas M. Priselac, Cedars-Sinai Health System
• Gary Pruden, Johnson & Johnson Company
• Michael J. Swinford, GE Healthcare
• Richard Umbdenstock, American Hospital Association
• Dan Wolterman, Memorial Hermann Healthcare System

“The response from accredited health care organizations to the Center has been extremely positive, a fact due in large part to the ongoing commitment of participating hospitals and health systems and sponsors to address the toughest and most persistent problems facing health care across the country,” says Dr. Chassin. “The perspectives of the Leadership Advisory Council members will help us to bring everyone interested in safe, reliable health care together to create lasting solutions.”

Established in 2009, the Joint Commission Center for Transforming Healthcare aims to solve health care’s most critical safety and quality problems. The Center’s participants — which include some of the nation’s leading hospitals and health systems — use a systematic approach to analyze specific breakdowns in care and discover their underlying causes to develop targeted solutions that solve these complex problems. Center projects include hand hygiene, wrong-site surgery, hand-off communications and the reduction of surgical site infections (SSI) following colorectal surgery. Future projects are expected to focus on preventable hospitalizations, medication errors, and other aspects of infection control.

All Joint Commission-accredited health care organizations can access the solutions on their secure Joint Commission Connect extranet through the Targeted Solutions Tool™ (TST). The TST provides a step-by-step process to measure performance, identify barriers to excellent performance, and implement the Center’s proven solutions that are customized to address an organization’s specific barriers.

The first set of targeted solutions, created by eight hospitals and health care systems working in collaboration with the Center, focuses on improving hand hygiene. The second set of solutions, announced last week, focuses on improving hand-off communications. The targeted solutions for hand-off communications will be pilot tested to prove their effectiveness in demographically diverse hospitals and will be added to the TST in the second half of 2011.

For more information about the Joint Commission Center for Transforming Healthcare, visit www.centerfortransforminghealthcare.org.

Established in 2009, the Joint Commission Center for Transforming Healthcare aims to transform American health care into a high-reliability industry that ensures patients receive the safest, highest quality care they expect and deserve. The Center’s participants — the nation’s leading hospitals and health systems — use a proven, systematic approach to analyze specific breakdowns in care and discover their underlying causes to develop targeted solutions for health care’s most critical safety and quality problems. The Center is a not-for-profit affiliate of The Joint Commission, which shares the Center’s proven effective solutions with its more than 18,000 accredited health care organizations. Learn more about the Center at www.centerfortransforminghealthcare.org.

To view this release in a media-rich format, go to: http://www.pwrnewmedia.com/2010/jointcommission_01028_leadership_council/index.html

Click here to see all recent news from this company

WARREN, NJ–(Marketwire – October 28, 2010) –  Health care reform has spawned a host of privacy, information security and other liability exposures for the emerging healthcare information technology industry. In response, the Chubb Group of Insurance Companies has established a program to address the industry’s specialized risk needs.

“Chubb has brought together its information and network technology and life sciences expertise to tailor insurance and loss control solutions to this rapidly growing market sector,” said Stephen Harris, a Chubb vice president and co-program manager.

More than 1,000 companies supply information technology products and services to the healthcare and medical research industries in the United States and Canada. The sector is poised for additional growth after the allocation of nearly $20 billion in federal stimulus funds to incentives to create electronic health records and to other investments in the sector.

“Chubb’s Healthcare Information Technology program will provide insurance products and services, on a global basis, that can help this emerging industry face privacy and information security requirements, as well as a host of new professional liability exposures,” said Richard Reed, a Chubb vice president and co-program manager.

An integrated liability solution from Chubb can help protect healthcare information technology companies from:

• general and products liability when software or hardware that is defective or contains inaccurate or incomplete information causes or contributes to patient injuries;
• errors and omission liability when a product defect or service deficiency results in economic injury to a customer;
• third-party liability to patients, healthcare providers and others associated with database security breaches; and
• costs incurred to comply with state, federal and foreign laws requiring companies to notify consumers of a privacy data breach.

In addition, Chubb can provide these firms with insurance addressing property, business interruption, workers compensation and auto exposures.

The member insurers of the Chubb Group of Insurance Companies form a multi-billion dollar organization providing property and casualty insurance for personal and commercial customers worldwide through 8,500 independent agents and brokers. Chubb’s global network includes branches throughout North America, Europe, Latin America, Asia and Australia.

CLARK, NJ–(Marketwire – October 28, 2010) –  HealthEd, a specialized agency focused on turning health education into positive outcomes, today announced several key senior-level appointments — Mike Brzozowski as chief strategy officer, Sonja “Sunny” Foster-Storch as executive vice president, managing director for HealthEd, and Paul Steiner as executive vice president, managing director for Encore, a HealthEd company. With these additions to the executive leadership team, HealthEd Group signals its focus on expanding its strategic and consultative services to meet changing client needs.

“We are very excited to have Mike, Sunny, and Paul on board,” said Roy Broadfoot, CEO and president of HealthEd. “The business needs and requirements of our clients are becoming increasingly complex. We have heard them and have responded by recruiting top executives who can strategically lead our cross-functional teams to deliver innovative and engaging solutions.”

Mr. Brzozowski comes to HealthEd with more than 20 years of experience in relationship marketing, strategic planning, and business analysis. He is responsible for leading and expanding strategic marketing and health education consulting services. With Mr. Brzozowski at the helm, the health educators and marketers combine to provide a unique insight into patient motivations and behaviors. Most recently, Mr. Brzozowski worked at Draftfcb as executive vice president of customer relationship marketing and before that was at Ogilvyone Worldwide as senior partner, executive director of relationship marketing strategy.

Ms. Foster-Storch will lead HealthEd’s client services group, while Mr. Steiner will lead Encore’s. The two help form a structured leadership team for both organizations by integrating resources and focusing on client development. Both report directly to Larry Moran, chief operating officer.

Ms. Foster-Storch comes to HealthEd from The CementBloc, where she led the market development and marketing strategy team. Before that, she cofounded Clinical CONNEXION, a medical education company. 

Mr. Steiner joins Encore from Draftfcb, where he was senior vice president, director of customer relationship marketing. Previously, he served as senior vice president, group account director, at Omnicom’s Unit 7 relationship marketing agency. 

“Sunny and Paul both bring over 20 years of strategic planning and healthcare marketing experience to our company,” said Anita St. Clair, HealthEd’s chief client development officer. “And Mike’s success in creating integrated marketing solutions is just what the doctor ordered. His belief that effective relationship marketing helps deliver engaging, individualized, dialog-driven customer experiences aligns perfectly with our clients’ needs and our company mission.”

About HealthEd
HealthEd is a specialized agency that uses education to help people develop the knowledge, skills, motivation, and confidence to manage important health decisions and activities and ultimately achieve better health outcomes. For more information about HealthEd and the services we offer, please visit http://www.HealthEd.com or contact Anita St. Clair, chief client development officer, at 908-389-2133.

Click here to see all recent news from this company

TAMPA, FL–(Marketwire – October 28, 2010) –  The Certification Commission for Health Information Technology (CCHIT^®) today announced that Visionary HealthWare’s Alteer Office 8.0 is a pre-market CCHIT Certified^®  2011 Ambulatory EHR. Ambulatory EHRs are designed for physician offices and clinics where most Americans get their healthcare. Alteer Office is part of Visionary HealthWare’s offerings of practice management and electronic healthcare record solutions. Visionary HealthWare is a subsidiary of CompuGroup Medical U.S.

As a CCHIT Certified 2011 product, Visionary HealthWare’s Alteer Office demonstrated compliance with the advanced ePrescribing module requirements and has passed all required criteria in the CCHIT 2011 Ambulatory and Security test scripts for:

• Functionality (ability to create and manage electronic records for all patients, as well as automating workflow in a physician’s office),
• Interoperability (ability to receive and send electronic data to other entities such as laboratories), and
• Security (ability to keep patients’ information safe).

The CCHIT Certified program is an independently developed certification that includes a rigorous inspection of an EHR’s integrated functionality, interoperability, and security using criteria developed by CCHIT’s broadly representative, expert work groups. By looking to products with the CCHIT Certified seal, physicians and other providers can be assured they are making a reliable investment and insurers and other payers know the products meet expected industry standards. This program is intended to serve health care providers looking for greater assurance that a product will meet their complex needs.

“We believe that achieving CCHIT Certification confirms the quality and comprehensiveness of Visionary HealthWare’s Alteer Office as well as validates VHW’s commitment to providing our customers with the most up-to-date advancements in healthcare IT,” said Chris Grady, CIO of Visionary HealthWare. “Alteer Office provides the features, functionality, and ease of use necessary for physicians to adopt the EHR quickly while minimizing disruption to their current workflow.”

“Visionary HealthWare’s solution improves clinical outcomes by providing more comprehensive and timely information for clinical decision-making, and decreases time spent on administrative activities that can better be spent on direct patient care,” adds Jason Patchen, CEO of Visionary HealthWare. “All of these improvements contribute to a safer care environment for patients.”

About Visionary HealthWare
Visionary HealthWare (VHW) is a provider-based healthcare information technology company with operations in Florida, California and Maryland. VHW delivers innovative, effective, easy-to-use, services and software solutions designed to manage patient, clinical and financial information at all levels while helping practices prove “meaningful use”. Solutions include fully integrated Electronic Health Records, Practice Management, Laboratory Information Systems, Revenue Cycle Management, Document Management, e-Prescribing, and services for any size practice. VHW reaches over 60,000 providers nationwide and was ranked by Healthcare Informatics Magazine in the top 100 Healthcare Information Technology companies in America. VHW brands include Visionary Medical Systems, Antek HealthWare, Soft-Aid, USMD, and Alteer Corporation. Visionary HealthWare (www.visionaryhealthware.com). Visionary HealthWare is a subsidiary of CompuGroup Medical U.S.

About CompuGroup Medical

CompuGroup Medical is one of the leading e-health companies worldwide. Its software products, designed to support all medical and organizational activities in doctors’ offices and hospitals, its information services for all parties involved in the healthcare system and its web-based personal health records, contribute towards safer and more efficient healthcare.

The services of CompuGroup Medical are based on its unique customer base of around 370,000 doctors, dentists, hospitals and networks as well as other service providers. CompuGroup Medical is the e-Health company with one of the biggest coverage among e-health service providers worldwide. The company operates in 14 European countries as well as in Malaysia, Saudi Arabia, South Africa and in the USA and currently employs around 3,000 people.

ABOUT CCHIT
The Certification Commission for Health Information Technology (CCHIT®) is an independent, 501(c)3 nonprofit organization with the public mission of accelerating the adoption of robust, interoperable health information technology. The Commission has been certifying electronic health record technology since 2006 and is recognized by the Office of the National Coordinator for Health Information Technology (ONC), U.S. Department of Health and Human Services (HHS) as an Authorized Testing and Certification Body (ONC-ATCB). More information on CCHIT, CCHIT Certified® products and HHS certified electronic health record technology is available at http://cchit.org and http://ehrdecisions.com. 

“CCHIT®” and “CCHIT Certified®” are registered trademarks of the Certification Commission for Health Information Technology.

WALNUT CREEK, CA–(Marketwire – October 28, 2010) –  Dr. Mark Wolpa, founder of the Bay Area Foot & Laser Podiatry Group, is proud to announce that the PinPointe laser has received official FDA clearance for the treatment of toenail fungus. PinPointe™ is the first and only laser to receive this coveted FDA clearance specifically for treating toenail fungus, an embarrassing infection that causes a thickening and yellowing of the toenails. It is estimated that about 10 percent — or nearly 35 million adults in the United States alone have this embarrassing condition.

The PinPointe™ FootLaser™ is the only laser that has been clinically proven and has passed the rigorous testing by the FDA to receive clearance. Dr. Wolpa has successfully treated over 1600 patients and has seen dramatic results. “After many years of not having a successful way to treat my patients suffering with toenail fungus, I am thrilled to see such positive results using this leading edge laser technology,” says Dr. Wolpa.

About Bay Area Foot & Laser Podiatry Group

The Bay Area Foot & Laser Podiatry Group’s Dr. Mark Wolpa is Board Certified by the American Board of Podiatric Surgery and has been in practice in the Bay Area for over 30 years. He was the Chief of Podiatry at Alta Bates-Summit Hospital in Berkeley for the past 10 years and has authored articles, books, and appeared on radio and television programs discussing foot problems.

He has offices in Berkeley, Walnut Creek, Santa Rosa, and Marin. For more information about Dr. Wolpa and The PinPointe FootLaser visit www.BayAreaFootandLaser.com

Click here to see all recent news from this company

SUN VALLEY, CA–(Marketwire – October 28, 2010) –  XTend Medical, (PINKSHEETS: XMDC), a company that specializes in delivering life changing medical technology to healthcare organizations globally, announced today that the company will soon be launching a new website within the next few weeks. The company issued the following statement:

“XTend has contracted with GoDaddy’s website design professionals to build a new website for the company. After the issues they ran into last year using an independent web developer, the need for professionally trained web engineers and graphics persons was instrumental in their decision to have the GoDaddy Team of experts build out the site. The information has been sent to the website team and we’re awaiting the Beta version so we can make any last minute changes before launching the new site. We expect to have the site live within the next week or so and feel this new site will properly represent the company in cyberspace.”

In other news, the company is working to position itself so the auditing process for becoming a fully reporting company is met and the company is strategically positioned to attract the proper investment structure to commercialize the BioHarp. Any changes made to the company will be done in accordance with corporate counsel’s advice and with the future of the company and its shareholders securely in the minds of management. 

About XTend Medical
XTend Medical is a company that specializes in the sales, manufacturing and distribution of the latest in medical devices and telemedicine solutions for the healthcare industry. Their dedication to insuring the products and services offered to healthcare organizations, third-world countries, and physician groups are at the forefront of medical technology. Their recent acquisition of the BioHarp medical device will assist the company in becoming known as a leader in the healthcare sector globally. For further information, please contact them at [email protected] or visit their website at www.bioharpunius.com

Forward-Looking Statements

This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.